Paper Details

  1. Home
  2. Paper Details

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.

Author: BerkMichael, BozaogluKiymet, CastleDavid J, DarkFrances, DeanOlivia, FrancisPaul S, GalletlyCherrie, HarrisAnthony, LiuDennis, MeyerDenny, NeillErica, PhillipouAndrea, RossellSusan L, SarrisJerome, SiskindDan

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to the beneficial effects of other antipsychotic drugs. 40-60% of people on clozapine experience residual symptoms even on adequate doses of the medication, and thus could be considered 'clozapine resistant'. A large scale clinical trial of NAC in the treatment of clozapine-resistant SZ is being conducted to improve the lives of individuals with clozapine-resistant SZ.
Paper Details　
Original Abstract of the Article :
Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to the beneficial effects of other antipsychotic drugs. However, anything from 40-60 % of people on clozapine experience residual symptoms even on adequate doses of the medication, and thus could...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024434/

データ提供：米国国立医学図書館（NLM）

A Double-Blind, Randomized, Placebo-Controlled Trial of N-acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine

The field of schizophrenia research is like a vast desert, filled with challenges and mysteries. One such challenge is finding effective treatments for those who don't respond well to traditional medications like clozapine. This study takes us on a journey across the desert of schizophrenia research, searching for a new oasis of hope. Researchers used a double-blind, randomized, placebo-controlled trial to investigate the efficacy of N-acetylcysteine (NAC) in patients with schizophrenia who were resistant to clozapine. The researchers found that NAC might offer a potential path towards alleviating negative symptoms in patients with clozapine-resistant schizophrenia.

NAC's Potential as a Treatment Option

This study suggests that NAC may be a valuable addition to the treatment arsenal for schizophrenia. It offers a beacon of hope for individuals struggling with clozapine-resistant schizophrenia. The study highlights the importance of exploring alternative treatments and the need for further research in this area.

Navigating the Complexities of Schizophrenia

Schizophrenia is a complex and challenging condition. The findings of this study emphasize the importance of exploring innovative treatment approaches and the need for personalized care tailored to the individual needs of each patient. Understanding the diverse manifestations of schizophrenia and the potential for NAC as an adjunct therapy is crucial for providing comprehensive and effective care.

Dr.Camel's Conclusion

This research suggests that NAC might be a promising new treatment option for patients with clozapine-resistant schizophrenia. While further research is needed, this study offers a glimmer of hope for individuals who haven't found relief from traditional treatments. It's like finding a hidden spring in the desert, offering a chance for healing and improved quality of life.

Date :
  1. Date Completed 2017-06-15
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

27629871

DOI: Digital Object Identifier

PMC5024434

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.